Answers are grounded in this paper and cite their sources.
Selective serotonin reuptake inhibitors (SSRIs) are widely used during pregnancy, but whether individual SSRIs differ in their developmental toxicity and long-term effects on offspring remains insufficiently understood. In this study, we comparatively evaluated prenatal exposure to sertraline, fluoxetine, and escitalopram in mice, with particular emphasis on maternal–fetal exposure, organ-specific developmental effects, and persistence of these alterations into adulthood. Pregnant mice received low or high doses of each SSRI from gestational day 0–18. Maternal and fetal biochemical profiles, fetal growth, organ morphology, and developmental markers were assessed, followed by evaluation of corresponding phenotypes in adult offspring. A high-fat diet (HFD) challenge was additionally applied to offspring prenatally exposed to low-dose sertraline to assess susceptibility to later-life metabolic stress. All three SSRIs crossed the placenta and altered maternal–fetal serotonergic homeostasis, but their developmental effects showed clear drug- and organ-specific patterns. The fetal brain exhibited relatively consistent susceptibility across exposure groups, whereas sertraline predominantly disrupted hepatic lipid metabolism and fluoxetine altered developmental markers in the kidney and gonads; escitalopram produced comparatively limited effects. Most fetal alterations in the brain, kidney, and gonads were not accompanied by detectable functional abnormalities at postnatal week 12. In contrast, sertraline-associated hepatic abnormalities, including increased FASN and CD36 expression and lipid accumulation, persisted into adulthood. Prenatal low-dose sertraline exposure also impaired glucose tolerance and insulin sensitivity and exacerbated HFD-induced hepatic lipid accumulation and metabolic injury. These findings demonstrate that developmental toxicity differs substantially among individual SSRIs despite their shared pharmacological class and highlight the importance of drug- and organ-specific evaluation in the long-term safety assessment of prenatal SSRI exposure.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: